Memo Therapeutics is a company operating in the field of antibody discovery and immune repertoire analysis. Its DROPZYLLA platform creates a recombinant in vitro copy of an individual’s B cell and antibody repertoire, which is then banked as a library. The company develops a therapeutic antibody lead pipeline with an initial focus on infectious diseases and cancer.